skip to Main Content

July 24, 2022
2022 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

July 18, 2022
TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast
In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.

June 7, 2022
Test and Treat COVID-19: An Advocate’s Introduction to SARS-CoV-2 Rapid Diagnostic Testing
All people have the right to know their COVID-19 status and to be able to use that information to protect themselves, their families, and their communities. Rapid antigen tests can be used at home or in informal settings to reliably and quickly detect cases of COVID-19, to guide decisions on…

June 3, 2022
2021 Annual Report
This year we celebrate the unending dedication and accomplishments of TAG’s staff. They persevered through the challenges of an ongoing pandemic in 2021 to find new ways to carry out our work.

April 20, 2022
Test and Treat COVID-19: Community Guide to Molnupiravir
This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about molnupiravir: what it is, how to take it, who should use it (and who should not,) and how it interacts with other drugs.

April 11, 2022
Test and Treat COVID-19: Community Guide to Paxlovid
Paxlovid can reduce the risk of hospitalization or death by 89% when taken shortly after testing positive for COVID-19. This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about Paxlovid: what it is, who should use it, how to take it, and how…

April 7, 2022
Community-led Monitoring for Access to Tuberculosis Screening and Diagnostic Testing
People at risk of tuberculosis (TB) have a right to TB screening and diagnostic testing in accordance with the standard of care recommended by the World Health Organization (WHO). Yet, many countries with high burdens of TB have limited uptake of WHO-recommended tools, such as rapid molecular tests and urine-LAM…

February 18, 2022
European Commitments to TB R&D Investments: Promises Made to Be Broken?
In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.

Back To Top